LONDON (Reuters) – AstraZeneca expects to produce more than 100 million doses of its COVID-19 vaccine – developed with Oxford University – this month, ramping up to more than 200 million a month by April, Chief Executive Pascal Soriot said on Thursday.
Mene Pangalos, head of BioPharmaceuticals R&D at the British drugmaker earlier said the company expects much-anticipated data for the late-stage U.S. trial of its vaccine before the end of March.
A read-out on data is “only weeks away”, he said on a media call after release of the company’s 2020 results.
(Reporting by Pushkala Aripaka and Ludwig Burger; Writing by Josephine Mason; Editing by David Goodman)
